Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AbCellera Biologics Inc. (ABCL)

7.135   -0.025 (-0.35%) 06-09 13:23
Open: 7.19 Pre. Close: 7.16
High: 7.23 Low: 7.02
Volume: 1,152,189 Market Cap: 2,060(M)

Technical analysis

as of: 2023-06-09 12:43:06 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 8.83     One year: 10.31
Support: Support1: 6.3    Support2: 5.53
Resistance: Resistance1: 7.55    Resistance2: 8.83
Pivot: 6.87
Moving Average: MA(5): 7.06     MA(20): 6.61
MA(100): 7.88     MA(250): 9.77
MACD: MACD(12,26): 0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 80.7     %D(3): 77.1
RSI: RSI(14): 59.3
52-week: High: 14.97  Low: 5.53
Average Vol(K): 3-Month: 2,143 (K)  10-Days: 2,737 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ABCL ] has closed below upper band by 29.5%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.36 - 7.39 7.39 - 7.42
Low: 6.9 - 6.95 6.95 - 6.98
Close: 7.09 - 7.16 7.16 - 7.21

Company Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Headline News

Fri, 09 Jun 2023
American Century Companies Increases Stake in AbCellera ... - Best Stocks

Fri, 09 Jun 2023
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Bought by ... - MarketBeat

Thu, 08 Jun 2023
Guru Fundamental Report for ABCL - Benjamin Graham - Nasdaq

Wed, 07 Jun 2023
Should You Accumulate AbCellera Biologics Inc (ABCL) Stock Wednesday Morning? - InvestorsObserver

Mon, 29 May 2023
2023-05-29 | NDAQ:ABCL | Press Release | AbCellera Biologics Inc. - Stockhouse Publishing

Mon, 29 May 2023
AbCellera to Present at the Goldman Sachs 44th Annual Global ... - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 289 (M)
Shares Float 210 (M)
% Held by Insiders 28.6 (%)
% Held by Institutions 46.4 (%)
Shares Short 26,620 (K)
Shares Short P.Month 23,590 (K)

Stock Financials

EPS -0.19
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.19
Profit Margin (%) -27.8
Operating Margin (%) -40.5
Return on Assets (ttm) -3
Return on Equity (ttm) -4.2
Qtrly Rev. Growth -96.1
Gross Profit (p.s.) 1.07
Sales Per Share 0.62
EBITDA (p.s.) -0.16
Qtrly Earnings Growth 0
Operating Cash Flow 133 (M)
Levered Free Cash Flow 86 (M)

Stock Valuations

PE Ratio -39.67
PEG Ratio -1.2
Price to Book value 1.7
Price to Sales 11.38
Price to Cash Flow 15.49

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.